Debt Facility

30th Apr 2025 10:39

RNS Number : 8328G
Templeton Emerging Markets IT PLC
30 April 2025
 

Templeton Emerging Markets Investment Trust PLC (the "Company")

Legal Entity Identifier: 5493002NMTB70RZBXO96

30 April 2025

 

Debt Facility

On 29 April 2025, the Company drew down CNH300 million for one month under its existing £122 million revolving loan facility and on 30 April 2025 the Company repaid £40 million of the £80 million currently drawn down in pounds sterling.

 

Therefore, with effect from 30 April 2025, the Company's debt consists of £40 million and CNH300 million. At current exchange rates, CNH300 million is equivalent to approximately £31 million and therefore the Company's total debt is approximately £71 million.

 

There is a margin of 1.1% per annum over the relevant market reference rate on drawings in any of the three currencies allowed under the facility (GBP, USD or CNH) and a commitment fee of 0.40% per annum on undrawn amounts.

 

The Company has no other debt. As of 30 April, the Company's net gearing position based on the latest available net asset value ('NAV') is 0.0% (net of cash in the portfolio).

 

 

For further information please email [email protected]

 

 

The information contained in this announcement is restricted and is not for publication, release or distribution in the United States of America, any member state of the European Economic Area, Canada, Australia, Japan or the Republic of South Africa.

 

 

END

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPKKBNCBKKFQN